Perspective Therapeutics (CATX) Price & Analysis

Compare

1,392 Followers

CATX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.60 - $16.55

Previous CloseN/A

Volume311.62K

Average Volume (3M)841.45K

Market Cap

$289.63M

Enterprise Value$67.36M

Total Cash (Recent Filing)$226.92M

Total Debt (Recent Filing)$4.06M

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Nov 18, 2025

EPS Estimate

-0.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.30

Shares Outstanding74,262,990

10 Day Avg. Volume684,383

30 Day Avg. Volume841,447

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.23

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.84

Forecast

1Y Price Target

$13.22

Price Target Upside238.97% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Clinical ProgressPerspective Therapeutics is progressing three Pb-212-based clinical-stage radiopharmaceutical therapies, including the VMT-α-NET RPT designed to target and deliver Pb212 to SSTR2-expressing gastroenteropancreatic neuroendocrine tumors.

Efficacy And SafetyPb-212-VMT-α-NET continues to demonstrate a safe and well tolerated profile with no records of dose-limiting toxicities, no discontinuations due to adverse events, no treatment-emergent adverse events of Grade IV or higher, and no deaths.

Regulatory ApprovalPerspective Therapeutics has reached alignment with the FDA to open Cohort 3 of its ongoing Phase I/IIa trial of Pb-212-VMT-α-NET in advanced RPT-naive NETs.

Bears Say

Data UncertaintyThe group in Cohort 2 had not received sufficient follow-up for interpretable efficacy data, which introduces uncertainty regarding the efficacy outcomes.

Dose Escalation ConcernsAnti-tumor activity has already been reported in Cohort 2 and while renal toxicity has not been observed/reported so far, it is prudent to escalate targeted alpha therapy dose with care to limit risk to patients.

Serious Adverse EventsThere were records of 2 serious adverse events, but they were unrelated to the treatment.

Perspective Therapeutics News

Perspective Therapeutics reports Q2 EPS (29c), consensus (29c)

Reports Q2 revenue $300,000, consensus $170,370. Cash, cash equivalents, and short-term investments as of June 30 were approximately...

3d ago

CATX

Trust healthcare analyst holds analyst/industry conference call

Healthcare Goonewardene discusses Neuroendocrine Tumors (relevant companies EXEL, CATX, BMY, NVS) on an Analyst/Industry conference call to be...

23d ago

BMY

NVS

Promising Clinical Pipeline and Strategic Investments Justify Buy Rating for Perspective Therapeutics

Analyst Justin Walsh from JonesTrading reiterated a Buy rating on Perspective Therapeutics and keeping the price target at...

12h ago

CATX

Perspective Therapeutics Reports Q2 2025 Progress and Financials

Perspective Therapeutics, Inc. ( ($CATX) ) has released its Q2 earnings. Here is a breakdown of the information...

2d ago

CATX

Positive Outlook for Perspective Therapeutics: Buy Rating Driven by Promising Clinical Developments and Strategic Progress

Oliver McCammon, an analyst from LifeSci Capital, maintained the Buy rating on Perspective Therapeutics. The associated price target...

2d ago

CATX

Perspective Therapeutics Reports Promising Study Results at ASCO

An update from Perspective Therapeutics ( ($CATX) ) is now available. On August 13, 2025, Perspective Therapeutics provided...

3d ago

CATX

CATX Upcoming Earnings Report: What to Expect?

Perspective Therapeutics, Inc. (CATX) is scheduled to report 2nd quarter earnings on 08/08/2025. Regarding Q2 estimates, Wall Street...

10d ago

CATX

Perspective Therapeutics Updates Radiopharmaceutical Platform Presentation

Perspective Therapeutics ( ($CATX) ) just unveiled an announcement. On August 1, 2025, Perspective Therapeutics updated its corporate...

14d ago

CATX

Perspective Therapeutics Updates Strategic Focus on Radiopharmaceuticals

Perspective Therapeutics ( ($CATX) ) has provided an announcement. On July 3, 2025, Perspective Therapeutics updated its corporate...

1M ago

CATX

Perspective Therapeutics management to meet with Piper Sandler

Luncheon Meeting to be held on July 8 hosted by Piper Sandler. Published first on TheFly – the...

1M ago

CATX

Buy Rating for Perspective Therapeutics: Clinical Advancements and Strategic Developments Drive Positive Outlook

Analyst Justin Walsh from JonesTrading reiterated a Buy rating on Perspective Therapeutics (CATX – Research Report) and keeping...

2M ago

CATX

Perspective Therapeutics Advances Phase 1/2a Clinical Trial

Perspective Therapeutics ( ($CATX) ) has provided an announcement. On June 21, 2025, Perspective Therapeutics announced FDA alignment...

2M ago

CATX

Perspective Therapeutics price target raised to $12 from $9 at B. Riley

B. Riley raised the firm’s price target on Perspective Therapeutics (CATX) to $12 from $9 and keeps a...

2M ago

CATX

Optimistic Buy Rating for Perspective Therapeutics Driven by Strategic Developments and Promising Clinical Data

Analyst Dennis Kennedy from LifeSci Capital maintained a Buy rating on Perspective Therapeutics (CATX – Research Report) and...

2M ago

CATX

CATX FAQ

What was Perspective Therapeutics’s price range in the past 12 months?

Perspective Therapeutics lowest stock price was $1.60 and its highest was $16.55 in the past 12 months.

What is Perspective Therapeutics’s market cap?

Perspective Therapeutics’s market cap is $289.63M.

When is Perspective Therapeutics’s upcoming earnings report date?

Perspective Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 94 days.

How were Perspective Therapeutics’s earnings last quarter?

Perspective Therapeutics released its earnings results on Aug 13, 2025. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.293 by -$0.007.

Is Perspective Therapeutics overvalued?

According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Perspective Therapeutics pay dividends?

Perspective Therapeutics does not currently pay dividends.

What is Perspective Therapeutics’s EPS estimate?

Perspective Therapeutics’s EPS estimate is -0.31.

How many shares outstanding does Perspective Therapeutics have?

Perspective Therapeutics has 74,262,990 shares outstanding.

What happened to Perspective Therapeutics’s price movement after its last earnings report?

Perspective Therapeutics reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.293. Following the earnings report the stock price went down -4.271%.

Which hedge fund is a major shareholder of Perspective Therapeutics?

Currently, no hedge funds are holding shares in CATX

Perspective Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-31.45%

Trailing 12-Months

Asset Growth

-19.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Perspective Therapeutics

Perspective Therapeutics (CATX) is a biotechnology company focused on developing innovative therapeutic solutions within the healthcare sector. The company specializes in the research, development, and commercialization of cutting-edge treatments aimed at addressing complex medical conditions. Their core products and services include advanced therapeutics and technologies designed to improve patient outcomes and enhance the effectiveness of existing treatment regimens.

Perspective Therapeutics (CATX) Earnings & Revenues

Historic Earnings Reports

CATX Stock 12 Month Forecast

Average Price Target

$13.22

▲(238.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","19":"$19","4.75":"$4.75","9.5":"$9.5","14.25":"$14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.75,9.5,14.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.68,4.781538461538462,5.883076923076923,6.984615384615385,8.086153846153847,9.187692307692307,10.28923076923077,11.390769230769232,12.492307692307692,13.593846153846155,14.695384615384615,15.796923076923077,16.89846153846154,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.68,4.413846153846154,5.147692307692308,5.881538461538462,6.615384615384616,7.34923076923077,8.083076923076923,8.816923076923077,9.550769230769232,10.284615384615385,11.018461538461539,11.752307692307692,12.486153846153847,{"y":13.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.68,3.8584615384615386,4.0369230769230775,4.2153846153846155,4.3938461538461535,4.572307692307692,4.750769230769231,4.929230769230769,5.107692307692307,5.286153846153846,5.464615384615385,5.643076923076923,5.821538461538461,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.8,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.63,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >